

NOV 05 2003
NOV 05 2003
I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:
Commissioner for Patents, P.O. Box 1450
Alexandria, VA 22313 on November 3, 2003.

Patent Application
Docket No. GJE-6757C1
Serial No. 10/617,847

David R. Saliwanchik

David R. Saliwanchik, Patent Attorney

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Bardsley *et al.*
Serial No. : 10/617,847
Art Unit : 1614
Conf. No. : 7988
Filed : July 10, 2003
For : New Therapeutic Use of 4-(2-Fluorophenyl)-6-Methyl-2-(1-Piperazinyl)Thieno[2,3-D]Pyrimidine

Office of Initial Patent Examination's Customer Service Center
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

REQUEST FOR CORRECTION OF FILING RECEIPT

Sir:

The applicants respectfully request the correction of errors in the Official Filing Receipt for the above-identified patent application. The error has occurred in the Foreign Applications Section. The correction needed is as follows:

UNITED KINGDOM 0112494.0 05/21/2002

Should read

UNITED KINGDOM 0112494.0 **05/22/2002**

Attached is a copy of the executed Declaration and Power of Attorney form that was submitted to the U.S. Patent Office. Please note that the Declaration and Power of Attorney notes that foreign priority application GB 0112494.0 was filed May 22, 2001, not May 21, 2001.

Applicants respectfully request that a corrected official Filing Receipt be issued referencing the correct filing date of GB 0112494.0.

Respectfully submitted,



David R. Saliwanchik

Patent Attorney

Registration No. 31,794

Phone No.: 352-375-8100

Address : 2421 N.W. 41st Street, Suite A-1
Gainesville, FL 32606-6669

DRS/la

Enclosures: Copy of erroneous Official Filing Receipt; and
Copy of executed Declaration and Power of Attorney form.



NOV 05 2003

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
 United States Patent and Trademark Office
 Address: COMMISSIONER FOR PATENTS
 P.O. Box 1450
 Alexandria, Virginia 22313-1450
 www.uspto.gov

APPL NO.	FILING OR 371 (c) DATE	ART UNIT	FIL FEE REC'D	ATTY. DOCKET NO	DRAWINGS	TOT CLMS	IND CLMS
10/617,847	07/10/2003	1614	750	GJE-6757C1		13	3

23557
 SALIWANCHIK LLOYD & SALIWANCHIK
 A PROFESSIONAL ASSOCIATION
 2421 N.W. 41ST STREET
 SUITE A-1
 GAINESVILLE, FL 326066669

COPY

CONFIRMATION NO. 7988

FILING RECEIPT



OC000000010999914

OCT 11 2003

LRS

Sh

Date Mailed: 10/09/2003

Receipt is acknowledged of this regular Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Filing Receipt Corrections, facsimile number 703-746-9195. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

Hazel Judith Bardsley, Cambridge, UNITED KINGDOM;
 David Cavalla, Cambridge, UNITED KINGDOM;
 Robert William Gristwood, Cambridge, UNITED KINGDOM;

D mestic Priority data as claimed by applicant

This application is a CIP of PCT/GB02/02388 05/21/2002

F reign Applications

Should be
 22
 UNITED KINGDOM 0112494.0 05/21/2002
 UNITED KINGDOM 0216027.3 07/10/2002

If Required, Foreign Filing License Granted: 10/07/2003

Projected Publication Date: To Be Determined - pending completion of Missing Parts

Non-Publication Request: No

Early Publication Request: No

Title

New therapeutic use of 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)thieno[2,3-D]pyrimidine

Preliminary Class

514

**LICENSE FOR FOREIGN FILING UNDER
Title 35, United States Code, Section 184
Title 37, Code of Federal Regulations, 5.11 & 5.15**

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).



COPY

Docket No. GJE-6757C1

DECLARATION (37 C.F.R. § 1.63) AND POWER OF ATTORNEY

As a below-named inventor, I hereby declare that:

My residence, post office address, and citizenship are as stated below next to my name; and

I believe that I am the original, first, and sole inventor (if only one name is listed below), or an original, first, and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled **New Therapeutic Use of 4-(2-Fluorophenyl)-6-Methyl-2-(1-Piperazinyl)Thieno[2,3-D]Pyrimidine**, specification for which

☐ is attached hereto.

☒ was filed July 10, 2003, Serial No. 10/617,847.

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to the patentability of this application in accordance with Title 37, Code of Federal Regulations, § 1.56 (a).

I hereby claim foreign priority benefits under Title 35, United States Code §119 and/or §365 of any foreign application(s) for patent or inventor's certificate listed below and have also identified any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed:

Application Serial No.	Country	Filing Date	Priority Claimed
PCT/GB02/02388	PCT	May 21, 2002	Yes
0112494.0	GB	May 22, 2001	Yes
0216027.3	GB	July 10, 2002	Yes

I hereby claim priority benefits under Title 35, United States Code §119 of any provisional application(s) for patent listed below:

Application Serial No.	Filing Date	Priority Claimed
---------------------------	-------------	------------------

I hereby claim the benefit under Title 35, United States Code, §120 and/or §365 of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application(s) in the manner provided by the first paragraph of Title 35, United States Code, §112, I acknowledge the duty to disclose material information as defined in Title 37, Code of Federal Regulations, §1.56(a) which became available between the filing date of the prior application and the national or PCT international filing date of this application:

Application Serial No.	Filing Date	Status (Patented, Pending, Abandoned)
---------------------------	-------------	--

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

I hereby appoint the following persons registered to practice before the Patent and Trademark Office as my attorneys with full power of substitution and revocation to prosecute this application and all divisions and continuations thereof and to transact all business in the Patent and Trademark Office connected therewith: John M. Sanders, Reg. No. 30,126; David R. Saliwanchik, Reg. No. 31,794; Jeff Lloyd, Reg. No. 35,589; Doran R. Pace, Reg. No. 38,261; Jay M. Sanders, Reg. No. 39,355; Jean Kyle, Reg. No. 36,987; James S. Parker, Reg. No. 40,119; Frank C. Eisenschenk, Reg. No. 45,332; Glenn P. Ladwig, Reg. No. 46,853; Margaret Efron, Reg. No. 47,545; and Gwendolyn L. Daniels, Reg. No. 51,594.

I request that all correspondence be sent to:

David R. Saliwanchik
Saliwanchik, Lloyd & Saliwanchik
A Professional Association
2421 N.W. 41st Street, Suite A-1
Gainesville, FL 32606-6669

I further request that all telephone communications be directed to:

David R. Saliwanchik
352-375-8100

Name of First or Sole Inventor Hazel Judith Bardsley
 Residence KONSTANZ GERMANY Citizenship British
Cambridge, United Kingdom
 Post Office Address ALTANA PHARMA AG BYK-GULDEN-STR. 2
c/o Arachnova Ltd, St. John's Innovation Centre
78467 KONSTANZ GERMANY HJB 28 July 2003
Cambridge CB4 0WS United Kingdom
Hazel Bardsley Date 28 July 2003
 Signature of First or Sole Inventor

Name of Second Joint Inventor David Cavalla
 Residence Cambridge, United Kingdom Citizenship British
 Post Office Address c/o Arachnova Ltd, St. John's Innovation Centre
Cambridge CB4 0WS United Kingdom
David Cavalla Date 31 July 2003
 Signature of Second Joint Inventor

Name of Third Joint Inventor Robert William Gristwood
 Residence Cambridge, United Kingdom Citizenship British
 Post Office Address c/o Arachnova Ltd, St. John's Innovation Centre
Cambridge CB4 0WS United Kingdom
Robert Gristwood Date 11 August 2003
 Signature of Third Joint Inventor

Name of Fourth Joint Inventor _____
 Residence _____ Citizenship _____
 Post Office Address _____

 Signature of Fourth Inventor Date _____